Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Jul;31(4):207–212. doi: 10.1007/BF01789170

A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays

R P Junghans 1,✉
PMCID: PMC11038913  PMID: 2379218

Abstract

As novel antibody therapeutics are developed for different malignancies and require evaluation with cells previously uncharacterized as antibody-dependent cellmediated cytotoxicity (ADCC) targets, efficient description of key parameters of the assay system expedites the preclinical assessment. A strategy is presented to define the behavior of cell lines or cell cultures as targets in ADCC assays, with emphasis on cytokine activation of effectors and attention to contributions of natural killer cells. Features of the target cell, the effector cell, and the assay itself are separately assessed. Target cells are evaluated for the kinetics of chromium labelling and release, and positive and negative control antibodies are selected. Effector cells are evaluated in ADCC for the impact of different donor sources, storage conditions, lymphokine concentration and duration of activation. The assay itself is assessed for the impact of the type of liquid medium, incubation duration, and effector-to-target ratio. Representative data are presented with a model human malignant T cell line, HuT102.

Keywords: Chromium, Natural Killer, Natural Killer Cell, Target Cell, Effector Cell

References

  • 1.Begley CG, Nicola NA, Metcalf D. Proliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSF. Blood. 1988;71:640. [PubMed] [Google Scholar]
  • 2.Berinstein N, Levy R. Treatment of murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol. 1987;139:971. [PubMed] [Google Scholar]
  • 3.Brown EJ, Joiner KA, Frank MM. Complement. In: Paul WE, editor. Fundamental immunology. New York: Raven Press; 1984. p. 645. [Google Scholar]
  • 4.Davitz MA. Decay-accelerating factor (DAF): a review of its function and structure. Acta Med Scand [Suppl] 1987;715:111. doi: 10.1111/j.0954-6820.1987.tb09911.x. [DOI] [PubMed] [Google Scholar]
  • 5.Dearman RJ, Stevenson FK, Wrightham M, Hamblin TJ, Glennie MJ, Stevenson GT. Lymphokine-activated killer cells from normal and lymphoma subjects are cytotoxic for cells coated with antibody derivatives displaying human Fc-gamma. Blood. 1988;72:1985. [PubMed] [Google Scholar]
  • 6.Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res. 1988;48:7140. [PubMed] [Google Scholar]
  • 7.Fauci AS. Immunomodulators in clinical medicine. Ann Int Med. 1987;106:421. doi: 10.7326/0003-4819-106-3-421. [DOI] [PubMed] [Google Scholar]
  • 8.Hinuma S, Naruo K, Shiho O, Tsukamoto K. Characteristics of murine non-specific killer cells induced in vivo by recombinant interleukin-2. Immunology. 1986;59:251. [PMC free article] [PubMed] [Google Scholar]
  • 9.Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA. 1986;83:7893. doi: 10.1073/pnas.83.20.7893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990;50:1495. [PubMed] [Google Scholar]
  • 11.Kabelitz D, Kirchner H, Armerding D, Wagner H. Recombinant interleukin 2 rapidly augments human natural killer activity. Cell Immunol. 1985;93:38. doi: 10.1016/0008-8749(85)90386-7. [DOI] [PubMed] [Google Scholar]
  • 12.Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol. 1988;141:3478. [PubMed] [Google Scholar]
  • 13.Liu AY, Robinson RR, Hellström KE, Murray ED, Chang CP, Hellström I. Chimeric mouse-human IgGl antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439. doi: 10.1073/pnas.84.10.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lotzova E, Herberman RB. Reassessment of LAK phenomenology: a review. Nat Immun Cell Growth Regul. 1987;6:109. [PubMed] [Google Scholar]
  • 15.Lovchik JC, Hong R. Antibody-dependent cell-mediated cytolysis (ADCC): analyses and projections. Prog Allergy. 1977;22:1. [PubMed] [Google Scholar]
  • 16.Müller-Eberhard HJ, Zalman LS, Chiu FJ, Jung G, Martin DE. Molecular mechanisms of cytotoxicity: comparison of complement and killer lymphocytes. J Rheumatol. 1987;14(Suppl 13):28. [PubMed] [Google Scholar]
  • 17.Munn DH, Cheung NKV. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res. 1987;47:6600. [PubMed] [Google Scholar]
  • 18.Nelson DL, Poplack DG, Holiman BJ, Henkart PA. ADCC against human erythrocyte target cells: role of the anti-target cell antibodies in determining lymphocyte killer activity. Clin Exp Immunol. 1979;35:447. [PMC free article] [PubMed] [Google Scholar]
  • 19.Nishimura Y, Yokoyama M, Araki K, Ueda R, Kudo A, Watanabe T. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. Cancer Res. 1987;47:999. [PubMed] [Google Scholar]
  • 20.Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibodydependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 1987;138:3566. [PubMed] [Google Scholar]
  • 21.Perez P, Hoffman RW, Titus JA, Segal DM. Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies. J Exp Med. 1986;163:166. doi: 10.1084/jem.163.1.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2: implications at the level of Tac antigen. J Exp Med. 1984;160:1126. doi: 10.1084/jem.160.4.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Robb RJ, Rusk CM, Yodoi J, Greene WC. Interleukin 2 binding molecule distinct from the Tac protein: Analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci USA. 1987;84:2002. doi: 10.1073/pnas.84.7.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Segal DM, Wunderlich JR. Targeting of cytotoxic cells with hetero-crosslinked antibodies. Cancer Invest. 1988;6:83. doi: 10.3109/07357908809077031. [DOI] [PubMed] [Google Scholar]
  • 25.Shaw ARE, Bleackley RC, Meryweather JP, Barr PJ. Modulation of human natural killer cell activity by recombinant human interleukin 2. Cell Immunol. 1985;90:547. doi: 10.1016/0008-8749(85)90219-9. [DOI] [PubMed] [Google Scholar]
  • 26.Shin ML, Hänsch G, Hu VW, Nicholson-Weller A. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. J Immunol. 1986;136:1777. [PubMed] [Google Scholar]
  • 27.Talmadge JE, Wiltrout RH, Counts DF, Herberman RB, McDonald T, Ortaldo JR. Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes. Cell Immunol. 1986;102:261. doi: 10.1016/0008-8749(86)90420-x. [DOI] [PubMed] [Google Scholar]
  • 28.Timonen T, Ortaldo JR, Herberman RB. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981;153:569. doi: 10.1084/jem.153.3.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Titus JA, Perez P, Kaubisch A, Garrido MA, Segal DM. Human K/natural killer cells lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol. 1987;139:3153. [PubMed] [Google Scholar]
  • 30.Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B. Response of resting human periferal blood natural killer cells to interleukin 2. J Exp Med. 1984;160:1147. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tsudo M, Goldman CK, Bongiovanni KF, Chan WC, Winton EF, Yagita M, Grimm EA, Waldmann TA. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci USA. 1987;84:5394. doi: 10.1073/pnas.84.15.5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ueno Y, Miyawaki T, Seki H, Matsuda A, Taga K, Sato H, Taniguchi N. Differential effects of rcombinant human interferongamma and interleukin 2 on natural killer cell activity of peripheral blood in early human development. J Immunol. 1985;135:180. [PubMed] [Google Scholar]
  • 33.Waldmann TA. Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. J Natl Cancer Inst. 1989;81:914. doi: 10.1093/jnci/81.12.914. [DOI] [PubMed] [Google Scholar]
  • 34.Zarling JM, Moran PA, Grosmaire LS, McClure J, Schriver K, Ledbetter JA. Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates. J Immunol. 1988;140:2609. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES